GNH USA

Europe — EMA

Icatibant Cipla

GNH USA supplies Icatibant Cipla (Icatibant), a bradykinin B2 receptor antagonist for hereditary angioedema attacks. Request a quote for global supply.

Icatibant

Request sourcing

1
Pack/s

What is Icatibant?

Icatibant, the active ingredient in Icatibant Cipla, is a bradykinin B2 receptor antagonist presented as an injectable solution for subcutaneous injection. It is used to treat acute attacks of hereditary angioedema in patients with confirmed diagnosis.

GNH USA supplies Icatibant Cipla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant distribution across multiple regions.

What is Icatibant used for?

Icatibant is indicated for the treatment of hereditary angioedema attacks, a condition mediated by excessive bradykinin activity.

Hereditary angioedema (HAE) attacks: rapid relief of swelling and associated symptoms during acute episodes.

What are the side effects of Icatibant?

Icatibant may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: discomfort at the injection site. - Redness: erythema around the injection area. - Headache: transient head pain.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical care. - Angioedema: new or worsening swelling of the face, lips, or airway. - Hypotension: marked drop in blood pressure.

What precautions apply to Icatibant?

Before using Icatibant, consider the following precautions. - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown; consider potential effects on infant. - Renal impairment: monitor closely, dosage may need adjustment. - Concomitant ACE inhibitors or ARBs: increased risk of angioedema; evaluate necessity. - Observation: monitor patient for hypersensitivity reactions after each injection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Icatibant interact with?

Icatibant can interact with other medicines; review the following.

Major Interactions (Avoid): - ACE inhibitors: may exacerbate bradykinin‑mediated angioedema. - Angiotensin receptor blockers: similar risk of increased angioedema. - Estrogen‑containing contraceptives: potential additive effect on bradykinin pathways.

Moderate Interactions (Monitor Closely): - Diuretics: monitor blood pressure and electrolyte balance. - Other bradykinin pathway modulators: assess cumulative effect on vascular permeability. - NSAIDs: may increase risk of edema; observe for worsening symptoms.

Frequently asked questions

What is Icatibant Cipla used for?+
Icatibant Cipla is used to treat acute attacks of hereditary angioedema (HAE). It works by rapidly reducing swelling and associated symptoms that occur during an HAE episode, providing relief for patients with a confirmed diagnosis.
How does icatibant work?+
Icatibant works as a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin from triggering vasodilation and increased vascular permeability, which are the primary mechanisms behind the swelling seen in hereditary angioedema.
What is the usual dose of icatibant?+
The dose of icatibant is determined by the prescribing healthcare professional based on the patient’s condition and clinical guidelines. Dosing regimens are individualized, and patients should follow the prescriber’s instructions without deviation.
Is icatibant safe in pregnancy or breastfeeding?+
Safety of icatibant in pregnancy and while breastfeeding has not been established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.
How do I order Icatibant Cipla from GNH USA?+
To order Icatibant Cipla, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping (including cold‑chain where required) and import documentation.
How does icatibant compare with the main alternative drug?+
The primary alternative for HAE attacks is a C1‑esterase inhibitor (e.g., Berinert). Icatibant directly blocks the bradykinin B2 receptor, offering a rapid subcutaneous option, whereas C1‑esterase inhibitors replace deficient protein and are administered intravenously. Choice depends on clinical response, administration preferences and patient-specific factors.
How should Icatibant be stored and handled?+
Icatibant should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary temperature excursions occur, consult the product’s stability guidelines before use.
How is Icatibant administered?+
Icatibant is administered as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver. The site should be rotated for repeated doses to minimize local reactions.
What are the most serious risks to watch for?+
The most serious risks associated with icatibant include anaphylaxis, severe angioedema affecting the airway, and significant hypotension. Patients should be observed after injection for any signs of allergic reaction or worsening swelling and receive immediate medical attention if these occur.
Who should not use icatibant?+
Icatibant should not be used in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with a history of severe angioedema unrelated to hereditary angioedema, as well as those taking ACE inhibitors or ARBs without proper medical supervision.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Icatibant
Route
Subcutaneous Use
Manufacturer
Cipla Europe Nv
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU